Sam Fazeli, Sonic AI

Skip to content

Home Discover Library Ask Sonic Projects

Use with Claude or ChatGPT

Home Discover Library Ask Sonic Projects

Use with Claude or ChatGPT

Sam Fazeli, Sonic AI

Home/Library/Sam Fazeli

S

Sam Fazeli

Person

11

Mentions

3

Episodes

11

Claims

Sam Fazeli, mentioned 11 times across podcast episodes and expert conversations analyzed by Sonic.

What Sam Fazeli has said

AbbVie's combined revenue from its drugs Skyrizi and Rinvoq is projected to approach well over $50 billion.

bullish·Sam Fazzelli

Neuroscience is emerging as a significant new frontier for drug development, driven by an improved scientific understanding of the brain.

bullish·Sam Fazzelli

Major pharmaceutical companies generally operate with profit margins of approximately 30%.

neutral·Sam Fazzelli

AbbVie's combined revenue from its drugs Skyrizi and Rinvoq is projected to approach well over $50 billion.

Expert perspectiveSam FazzelliJun 22

Neuroscience is emerging as a significant new frontier for drug development, driven by an improved scientific understanding of the brain.

Expert perspectiveSam FazzelliJun 22

Major pharmaceutical companies generally operate with profit margins of approximately 30%.

Expert perspectiveSam FazzelliJun 22

Most major pharmaceutical companies, including Pfizer, are highly cash-generative with low leverage, which positions them to pursue large acquisitions.

Expert perspectiveSam FazzelliJun 22

Despite its stock price halving since the peaks of the COVID-19 pandemic, Pfizer remains highly cash-generative and maintains a relatively low leverage ratio.

Expert perspectiveSam FazzelliJun 22

The acquisition of Apigee Therapeutics provides AbbVie with a new drug that gives it access to the eczema, or atopic dermatitis, market.

Expert perspectiveSam FazzelliJun 22

Eli Lilly's acquired asset from Colonia is a novel in-vivo CAR-T therapy for treating cancer, and recent data has been promising.

Expert perspectiveSam PizzelliJun 9

GSK's acquisition of Nuvalent is a strategic move to add two new drug candidates to its lung cancer portfolio.

Expert perspectiveSam PizzelliJun 9

Merck's recent sales beat was largely driven by a one-off inventory build, which is considered a low-quality beat by the market.

Expert perspectiveSam FazeliApr 30

Analyst expectations are for Eli Lilly's new oral obesity pill to generate $1.5 billion in sales in its first year.

Expert perspectiveSam FazeliApr 30

Eli Lilly raised its 2026 sales guidance by $2 billion, from a low-end of $80 billion to $82 billion, driven primarily by ex-US sales.

Expert perspectiveSam FazeliApr 30

Create a free account to see Sam Fazeli's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail